Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Cyst Fibros. 2018 Aug 23;18(1):94–101. doi: 10.1016/j.jcf.2018.07.011

Figure 1.

Figure 1.

Subgroup analysis of PEx rate ratio for LUM/IVA vs placebo at week 24. Data shown are rate ratio vs placebo from the pooled TRAFFIC and TRANSPORT studies for patients treated with LUM 400 mg q12h/IVA 250 mg q12h. Error bars represent 95% CIs. IVA, ivacaftor; LUM, lumacaftor; P aeruginosa, Pseudomonas aeruginosa; PEx, pulmonary exacerbation; ppFEV1, percent predicted forced expiratory volume in 1 second.